Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 8/20 | 0.41 |
| ▸ | GLP1R | P43220 | 7/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21087193 | 0.93 | FOLH1 (0.44) | FOLH1DGAT1GLP1RHDAC3HDAC4 | |
| SCHEMBL19369589 | 0.90 | EPHX2 (0.43) | FOLH1GLP1RHDAC3HDAC4HDAC1 | |
| SCHEMBL21087310 | 0.86 | DGAT1 (0.43) | FOLH1DGAT1 | |
| SCHEMBL21118058 | 0.86 | DGAT1 (0.42) | FOLH1DGAT1 | |
| SCHEMBL21087194 | 0.85 | FOLH1 (0.44) | FOLH1DGAT1GLP1RHDAC3HDAC4 | |
| SCHEMBL21087448 | 0.85 | GLP1R (0.52) | FOLH1DGAT1GLP1R | |
| SCHEMBL21087165 | 0.85 | DGAT1 (0.42) | FOLH1DGAT1 | |
| SCHEMBL21117258 | 0.83 | GLP1R (0.43) | FOLH1GLP1RHDAC3HDAC4HDAC1 | |
| SCHEMBL21117257 | 0.83 | GLP1R (0.43) | FOLH1GLP1RHDAC3HDAC4HDAC1 | |
| SCHEMBL21087164 | 0.80 | DGAT1 (0.42) | FOLH1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190175744-A1 | INSULIN-INCRETIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175744-A1 | INSULIN-INCRETIN CONJUGATES | GIPR, GLP1R, GCGR | FOLH1 320/4885DGAT1 315/4885GLP1R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.